Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children

Exclusion Criteria

• •1. Infant subject participating in other clinical trial or planned participation in another clinical trial during the present trial period
• •2. Infant with congenital or acquired immunodeficiency, malignancy or receiving immunosuppressive therapy.
• •3. Infant with history of allergy or systemic hypersensitivity to any of the vaccine component or to a vaccine containing the same substances.
• •4. Infant with history of epilepsy or a seizure disorder or neurodevelopmental disorders.
• •5. Clinical history of measles, mumps, or rubella infection.
• •6. Infants with leukemia, lymphoma, or any other cancer or neoplasm.
• •7. Acute or chronic, clinically significant pulmonary, endocrine, autoimmune, neurological, cardiovascular, metabolic, hepatic or renal functional abnormality, as determined by medical history, and physical examination tests, which in the opinion of the investigator, might interfere with the study objectives
• •8. Infant with any other condition, which, in the opinion of the investigator would jeopardize the safety or rights of the infant participating in the study or making it unlikely the subject could complete the protocol.